I am interested in health economics and health technology assessment, with a specific focus on developing cost-effectiveness models and policy frameworks to support sustainable funding for oncology treatments. My research interests lie in evaluating the economic and clinical value of oncology drugs, using data analytics to inform payer decision-making, and assessing real-world outcomes to drive equitable access for patients. Passionate about addressing the unique challenges in cancer care, I aim to contribute to pharmaceutical policies that prioritize high-value, evidence-based therapies, helping ensure that groundbreaking treatments are accessible to those who need them most.